FLOW CYTOMETRIC ASSESSMENT AND QUANTIFICATION OF SURFACE ANTIGENS IN DIFFUSE LARGE B CELL LYMPHOMA IN TARGET THERAPY ERA ON LYMPH NODE BIOPSIES (SIE 2026) - Oct 6, 2026 - Abstract #DP171; Pres time: Sep 22, 2026; 06:30 PM - 07:30 PM; Location: AREA POSTER; "At re- lapse, it was <20% in 2/32 (6.2%) and negative in 3/32 (9.3%) pts after rituximab or bispecific antibodies...At relapse, it was negative in 2/5 pts previously treated with Polatuzumab.ROR1, an new tar- get with selective expression on malignant cells, was ana- lyzed in 23 DLBCL and 16 mantle cell lymphoma (MCL). Its expression was very low in DLBCL (0.5% IQR 0.2-3.8) com- pared with MCL (96% IQR 0.7-99) (p 0.005).Our data show heterogeneous target antigen expression in DLBCL at diag- nosis and relapse. FC is a rapid and accurate method to quantify these antigens and may support treatment selec- tion and clinical decision-making in DLBCL."
Biopsy • IO biomarker • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin's Lymphoma • CD19 • CD20 • CD5 • CD79B • MME • PTPRC • ROR1
|
|
S. Bellesi1; E. Maiolo1; F. Campana3; C. Iacovelli1; E. Alma2; F. Bellisario2; M. Viscovo2,3; G. Schiaffini2,3; A. Bakacs4; D'Alò F2,3; S. Hohaus2,3
|